BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform rating on the shares. AbbVie (ABBV) drug Emraclidine’s failure to show a statistically significant benefit at the primary endpoint in both Phase 2 studies leaves Bristol’s Cobenfy “very well-positioned”, the analyst tells investors in a research note. With lackluster data pushing competitors back to the drawing board, the ball is now entirely in Bristol’s court to execute on its Cobenfy launch, the firm adds.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $39 from $36 at Morgan Stanley
- AbbVie price target lowered to $224 from $231 at Morgan Stanley
- Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure
- Bristol Myers price target raised to $60 from $55 at Citi
- Bristol Myers upgraded to Outperform from Market Perform at Leerink